Rivaroxaban - Dosing and Renal Function Effects

The presence of chronic kidney disease is an independent risk factor for increased bleeding events, including hemorrhagic stroke. Please carefully consider the risks and benefits of any oral anticoagulant prior to initiating therapy.


CrCl FDA Recommended Dose for Atrial Fibrillation FDA Recommended Dose for VTE Prevention in Ortho Surgery FDA Recommended Dose for VTE Treatment AUC T 1/2
> 80 ml/min 20mg daily 10mg daily 15mg bid for 21 days, then 20mg daily for remainder of treatment course - 8.3 hrs
50-80 ml/min 1.4 x increase 8.7 hrs
30-49 ml/min

CrCl 15-49 ml/min:     15mg daily

CrCl < 15ml/min:         avoid use

UWMedicine: RESTRICTED IF CrCl < 30 ml/min, consider alternative therapy

1.5 x increase 9 hrs
<30 ml/min

CrCl < 30ml/min: avoid use

UWMedicine: RESTRICTED IF CrCl < 30 ml/min, consider alternative therapy

CrCl< 30ml/min: avoid use

UWMedicine: RESTRICTED IF  CrCl < 30 ml/min, consider alternative therapy

1.6 x increase 9.5 hrs












Kubitza D et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. B J Clin Pharmacol 2010; 70:703-12.